

Interleukin-1 inhibits glucose-induced Ca^{2+} uptake by islets of Langerhans

Bryan A. Wolf^{*†}, Jonathan H. Hughes^{*}, Jon Florholmen^{*°}, John Turk^{**} and Michael L. McDaniel^{*}

^{*}Department of Pathology and [†]Division of Laboratory Medicine and Department of Internal Medicine, Washington University School of Medicine, Saint Louis; MO 63110, USA

Received 23 February 1989

Recombinant interleukin-1 (rIL-1) is known to inhibit glucose-induced insulin secretion by islets of Langerhans, a novel target tissue of cytokine. We have investigated whether rIL-1 pretreatment affects biochemical mechanisms known to be involved in the regulation of Ca^{2+} homeostasis during glucose-induced insulin secretion. Glucose-induced Ca^{2+} uptake by intact islets through the plasma membrane was dramatically inhibited (96%) by rIL-1 (2 nM). rIL-1, however, did not affect Ca^{2+} uptake by, or Ins 1,4,5- P_3 -induced Ca^{2+} efflux from, the endoplasmic reticulum in digitonin-permeabilized islets, although glucose-induced accumulation of inositol trisphosphates was inhibited (38%). These results suggest that perturbation of intracellular Ca^{2+} homeostasis in islets is involved in inhibition of insulin secretion by rIL-1.

Interleukin-1; Ca^{2+} uptake; Glucose; Inositol phosphate; (Pancreatic islet)

1. INTRODUCTION

The endocrine pancreas has recently been recognized to be a target tissue for interleukin-1 (IL-1) [1–5]. Recombinant IL-1 (rIL-1) exerts potent effects on glucose-induced insulin secretion by the β -cells of islets, the direction of which is determined by the concentration of rIL-1 and the duration of exposure [5]. Incubation of islets for several days with rIL-1 is believed to result in β -cell death [6]. Nerup and co-workers [6] have therefore proposed that rIL-1-mediated β -cell destruction may be an important pathogenic event in the development of insulin-dependent diabetes mellitus. The biochemical mechanisms underlying the cytotoxic effects of rIL-1 are unknown.

Moreover, it is difficult to assess the events involved in β -cell destruction once cytotoxicity has progressed to an irreversible stage. We have therefore begun to examine the biochemical actions of rIL-1 on β -cells at a time when suppression of insulin secretion is observed but before cytotoxicity has developed. An incubation period of 18 h was selected because at that time inhibition of glucose-induced insulin secretion is reversible upon removal of rIL-1, and the rIL-1-treated islets display no signs of cytotoxicity [3].

This experimental design has been employed to investigate the effects of rIL-1 on the biochemical mechanisms controlling Ca^{2+} homeostasis in islets [7–9].

2. MATERIALS AND METHODS

2.1. Islet isolation and culture

Islets of Langerhans were isolated from 8–15 rats per experiment by collagenase digestion, followed by separation on a discontinuous Ficoll gradient [10]. Isolated islets were cultured under an atmosphere of 95% air/5% CO_2 for 18 h at 37°C in 2.5 ml complete tissue culture medium (CMRL-1066 containing

Correspondence address: B.A. Wolf, Division of Laboratory Medicine, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA

[°] *Present address:* Department of Gastroenterology, University Hospital of Tromsø, Tromsø, Norway

5 mM D-glucose, 1% L-glutamine, 10% heat-inactivated fetal bovine serum, 0.5% penicillin and 0.5% streptomycin) supplemented with 2 nM rIL-1 (a gift from Dr P.T. Lomedico, Hoffman LaRoche, Inc., Nutley, NJ) or the vehicle [3]. Islets were then washed extensively in fresh complete tissue culture medium prior to use. Protein content of rIL-1-treated islets was identical to control islets [0.87 ± 0.04 ($n = 34$) μg protein/islet for control, 0.94 ± 0.05 ($n = 35$) μg protein/islet for rIL-1-treated islets].

2.2. Ca^{2+} uptake and Ca^{2+} efflux by intact islets

Ca^{2+} uptake by intact islets was assessed by measuring the $^{45}\text{Ca}^{2+}$ content of islets in a static incubation design (30 islets/tube) using a dual-isotope technique with [^3H]sucrose as the extracellular marker as described [11,12]. rIL-1-pretreated (2 nM for 18 h) and control islets were preincubated for 30 min at 37°C in 0.1 ml Hepes/Krebs buffer (25 mM Hepes, 115 mM NaCl, 5 mM KCl, 24 mM NaHCO_3 , 1 mM MgCl_2 , 2.5 mM CaCl_2 , pH 7.4) supplemented with 3 mM glucose and then incubated for 2, 5, and 60 min in 0.1 ml fresh Hepes/Krebs buffer containing $^{45}\text{Ca}^{2+}$ (2.5 mM, 12 mCi/mmol final specific activity) and [^3H]sucrose (5 mM, 6 mCi/mmol final specific activity) and 3 or 28 mM glucose. Ca^{2+} efflux experiments were performed on rIL-1-pretreated and control islets labeled overnight with $^{45}\text{Ca}^{2+}$ to isotopic equilibrium [13]. Radiolabeled islets were placed in a perfusion apparatus (450 islets/chamber) and perfused (1 ml/min) at 37°C with a modified Hepes/Krebs buffer supplemented with 3 or 28 mM glucose and which contained no added Ca^{2+} (final Ca^{2+} concentration = 0.003 mM) as in [12,13].

2.3. Inositol phosphate accumulation

Isolated islets were labeled to isotopic equilibrium with [^3H]inositol. In brief, islets were incubated for 135 min at 37°C with 400 μCi [^3H]inositol in 0.1 ml Hepes/Krebs buffer supplemented with 28 mM glucose [10,14]. Radiolabeled islets were then divided into two groups, each group being incubated for another 18 h at 37°C in 2.5 ml complete tissue culture medium supplemented with 50 μCi [^3H]inositol and 2 nM rIL-1 or vehicle. Radiolabeled islets were washed 3 times in Hepes/Krebs buffer to remove unincorporated [^3H]inositol, placed in silanized vials (400 islets/vial), preincubated for 30 min in Hepes/Krebs buffer with 3 mM glucose, and then incubated for another 30 min at 37°C in fresh Hepes/Krebs buffer with 3 or 28 mM glucose. Inositol phosphates were extracted and separated by anion-exchange HPLC as in [10,14].

2.4. Ca^{2+} fluxes in the endoplasmic reticulum of digitonin-permeabilized islets

rIL-1 pretreated (2 nM for 18 h) and control islets were permeabilized with digitonin as reported in [12]. Permeabilized islets (30/tube) were then incubated for 30 min in 100 μl of Pipes buffer mimicking intracellular conditions (100 mM Pipes, 100 mM KCl, 7 mM MgCl_2 , ± 5 mM ATP, 2.25 $\mu\text{g}/\text{ml}$ ruthenium red, pH 7.0). The free Ca^{2+} concentration of this buffer was set at 0.2 μM by including EGTA at a concentration of 0.11 mM. The $^{45}\text{Ca}^{2+}$ steady-state (30 min) content, the efflux of $^{45}\text{Ca}^{2+}$ (10 min) induced by Ins 1,4,5- P_3 (10 μM), and the efflux of $^{45}\text{Ca}^{2+}$ induced by A23187 (2 μM) from the endoplasmic reticulum of digitonin-permeabilized islets were measured as in [12].

3. RESULTS

3.1. Effect of rIL-1 on glucose-induced Ca^{2+} uptake and Ca^{2+} efflux by intact islets

Glucose-induced Ca^{2+} uptake by intact islets from the extracellular space was dramatically decreased in islets incubated for 18 h with 2 nM rIL-1. As shown in table 1, Ca^{2+} uptake in rIL-1-pretreated islets was inhibited by 69, 70 and 96% at 2, 5 and 60 min incubation ($p < 0.01$, $p < 0.05$, $p < 0.001$, respectively) following incubation with 28 mM glucose. rIL-1 pretreatment (2 nM for 18 h) had no effect on $^{45}\text{Ca}^{2+}$ accumulation of islets incubated with a basal concentration of glucose (3 mM).

In order to assess whether rIL-1 was exerting any effects on Ca^{2+} efflux from islets, a perfusion experimental design was employed. In the absence of extracellular Ca^{2+} , glucose is known to reduce Ca^{2+} efflux from perfused control islets loaded to isotopic equilibrium with $^{45}\text{Ca}^{2+}$ [8]. It was observed that rIL-1 pretreatment did not affect inhibition of Ca^{2+} efflux by glucose in such a perfusion system in comparison with control islets indicating that the efflux of Ca^{2+} from intact islets was not affected by pretreatment with rIL-1 (not shown).

Table 1

Effect of rIL-1 pretreatment (18 h) on glucose-induced Ca^{2+} uptake by intact islets

Incubation time (min)	Glucose-induced Ca^{2+} uptake (pmol/islet)	
	Control	2 nM rIL-1
2	1.18 ± 0.20	0.37 ± 0.19^b
5	1.16 ± 0.24	0.34 ± 0.27^a
60	3.36 ± 0.70	0.14 ± 0.64^c

^a $p < 0.05$ vs control

^b $p < 0.01$ vs control

^c $p < 0.001$ vs control

Glucose-induced Ca^{2+} uptake is calculated as the difference between the $^{45}\text{Ca}^{2+}$ content obtained at 28 mM glucose minus that at 3 mM glucose for each experimental condition as described in section 2. Control Ca^{2+} content at 3 mM glucose was 0.8 ± 0.2 , 1.2 ± 0.3 and 7.7 ± 0.6 pmol/islet at 2, 5 and 60 min, respectively. rIL-1 pretreatment had no effect on the Ca^{2+} content at 3 mM glucose (0.8 ± 0.3 , 1.2 ± 0.3 and 7.3 ± 0.7 pmol/islet at 2, 5 and 60 min, respectively). Results are shown as means \pm SE of 24–38 observations per condition from 4–5 experiments

3.2. Effect of rIL-1 on glucose-induced accumulation of inositol phosphates

Islets were labeled to isotopic equilibrium (overnight incubation) with [^3H]inositol in the presence or absence of 2 nM rIL-1. [^3H]Inositol-prelabeled islets were then incubated for 30 min with 3 or 28 mM glucose under conditions identical to those reported for insulin secretion studies [3]. In control islets, 28 mM glucose resulted in a significant increase (vs 3 mM glucose) in the accumulation of Ins P_1 ($24.9 \pm 10.1\%$, $p < 0.05$), Ins P_2 ($45.0 \pm 11.9\%$, $p < 0.001$), Ins 1,3,4- P_3 ($241.7 \pm 51.1\%$, $p < 0.001$), Ins 1,4,5- P_3 ($64.5 \pm 19.8\%$, $p < 0.02$), and Ins 1,3,4,5- P_4 ($49.7 \pm 15.2\%$, $p < 0.005$) (table 2). In rIL-1-pretreated islets, basal (3 mM glucose) accumulation of inositol phosphates was not significantly different from that of control islets. With rIL-1-pretreated islets however, accumula-

tion of inositol phosphates induced by 28 mM glucose was inhibited by 22% for Ins P_2 ($p < 0.02$), 38% for Ins 1,3,4- P_3 ($p < 0.01$), 20% for Ins 1,4,5- P_3 and 34% for Ins 1,3,4,5- P_4 ($p < 0.005$) (table 2). rIL-1 pretreatment had no effect on the inositol phospholipid content of islets (not shown).

3.3. Effect of rIL-1 on Ca^{2+} fluxes in the endoplasmic reticulum of permeabilized islets

Islets were pretreated for 18 h with 2 nM rIL-1 or with vehicle (control) and then permeabilized with digitonin to measure Ca^{2+} handling by the endoplasmic reticulum in situ. rIL-1 had no effect on the ATP-dependent Ca^{2+} steady-state content of the endoplasmic reticulum (0.38 ± 0.02 pmol/islet in control vs 0.39 ± 0.02 pmol/islet in rIL-1-pretreated islets; $n = 22-24$). Ins 1,4,5- P_3 ($10 \mu\text{M}$) mobilized $^{45}\text{Ca}^{2+}$ equally well from the endoplasmic reticulum of control (0.17 ± 0.03 pmol Ca^{2+} /islet) and from rIL-1-pretreated (0.21 ± 0.03 pmol Ca^{2+} /islet) islets. Similarly, the Ca^{2+} ionophore A23187 mobilized the same amount of Ca^{2+} from the endoplasmic reticulum of control islets (0.19 ± 0.02 pmol/islet) and from rIL-1-pretreated islets (0.18 ± 0.03 pmol/islet). These observations indicate that rIL-1 pretreatment for 18 h does not influence the ability of the endoplasmic reticulum to accumulate Ca^{2+} in the presence of ATP or to release Ca^{2+} in response to Ins 1,4,5- P_3 or the Ca^{2+} ionophore A23187.

4. DISCUSSION

Glucose-induced Ca^{2+} uptake by the β -cells was profoundly inhibited following rIL-1 pretreatment for 18 h. Basal Ca^{2+} uptake (in the presence of 3 mM glucose) was not affected. The lack of effect under basal conditions suggests that the integrity of the β -cell plasma membrane remained intact. Glucose stimulation of the normal β -cell results in plasma membrane depolarization, which is believed to be mediated by ATP-sensitive, voltage-independent K^+ channels [15]. Plasma membrane depolarization opens voltage-dependent Ca^{2+} channels which leads to an influx of extracellular Ca^{2+} [8]. It is currently believed that glucose-induced Ca^{2+} uptake, as measured in this study, represents the influx of Ca^{2+} through the voltage-dependent Ca^{2+} channels [8]. Such uptake is inhibited by Ca^{2+} channel blockers, and voltage-

Table 2

Effect of rIL-1 (2 nM) pretreatment (18 h) on glucose-induced accumulation of inositol phosphates

Incubation conditions	[^3H]Inositol phosphate accumulation (cpm)		
	Ins 1,4,5- P_3	Ins 1,3,4,5- P_4	Ins 1,3,4- P_3
3 mM glucose	129 ± 19	201 ± 17	68 ± 4
28 mM glucose	212 ± 26	301 ± 31	232 ± 35
3 mM glucose + 2 nM rIL-1 pretreatment	143 ± 22	161 ± 14	65 ± 6
28 mM glucose + 2 nM rIL-1 pretreatment	169 ± 19	199 ± 21	144 ± 21
% inhibition of 28 mM glucose-induced accumulation due to rIL-1	20 ± 9	34 ± 7^b	38 ± 9^a

^a $p < 0.01$ vs control

^b $p < 0.05$ vs control

Isolated islets were prelabeled with [^3H]inositol and incubated for 18 h in the presence or absence of 2 nM rIL-1 as described in section 2. Radiolabeled islets (300–350/tube) were preincubated for 30 min with 3 mM glucose and then incubated for another 30 min with 3 or 28 mM glucose. Inositol phosphates were extracted and analyzed by anion-exchange HPLC [10,14]. rIL-1 did not affect the incorporation of [^3H]inositol into phospholipids and inositol phosphates (802554 ± 52764 cpm [^3H]inositol incorporated in controls vs 819635 ± 77113 cpm for rIL-1-treated islets). Results are shown as means \pm SE of 5 separate experiments, each involving duplicate determinations

dependent inward Ca^{2+} currents have been directly recorded in islet cells (review [8]). Inhibition of Ca^{2+} uptake by rIL-1 may be due to a decrease in ATP concentrations which would prevent membrane depolarization mediated by ATP-induced closure of the K^{+} channels. rIL-1 has been shown to inhibit glucose oxidation in islets [4]. We are currently assessing ATP levels in rIL-1-treated islets.

The effect of rIL-1 on Ca^{2+} entry through the plasma membrane is apparently selective because rIL-1 did not influence Ca^{2+} handling by the endoplasmic reticulum. The participation of the endoplasmic reticulum in the control of islet cytosolic Ca^{2+} concentration is thought to be essential in glucose-induced insulin secretion [9]. rIL-1 influenced neither Ca^{2+} uptake by the endoplasmic reticulum nor Ca^{2+} efflux induced by the second messenger Ins 1,4,5- P_3 . These observations indicate that the endoplasmic reticulum itself functions normally after 18 h of exposure to rIL-1 even though glucose-stimulated inositol trisphosphate accumulation is perturbed.

In conclusion, we have shown that rIL-1 inhibits glucose-stimulated voltage-dependent entry of Ca^{2+} which suggests that perturbation of intracellular Ca^{2+} homeostasis may be involved in rIL-1 inhibition of insulin secretion.

Acknowledgements: The outstanding technical assistance of Connie Marshall, Joan Fink and Tom Stump has been greatly appreciated. We wish to thank Jane Huth and Jennifer Ferrell for expert secretarial assistance. This work was supported in part by a Juvenile Diabetes Foundation Fellowship (to B.A.W.), a Medical Scientist Training Grant T32-GM07200 (to

J.H.H.), a fellowship of the Norwegian Research Council for Science and the Humanities (to J.F.), NIH Grants DK34388, K04 DK01553, a Juvenile Diabetes Foundation International Grant 188471 (to J.T.), and NIH Grants DK06181 and DK03373 (to M.L.M.).

REFERENCES

- [1] Zawulich, W.S. and Diaz, V.A. (1986) *Diabetes* 35, 1119–1123.
- [2] Bendtzen, K., Mandrup-Poulsen, O.T., Nerup, J., Nielsen, J.H., Dinarello, C.A. and Svenson, M. (1987) *Science* 232, 1545–1547.
- [3] Comens, P.G., Wolf, B.A., Unanue, E.R., Lacy, P.E. and McDaniel, M.L. (1987) *Diabetes* 36, 963–970.
- [4] Sandler, S., Andersson, A. and Hellerstrom, C. (1987) *Endocrinology* 121, 1424–1431.
- [5] McDaniel, M.L., Hughes, J.H., Wolf, B.A., Easom, R.A. and Turk, J.W. (1988) *Diabetes* 37, 1311–1315.
- [6] Nerup, J., Mandrup-Poulsen, T. and Molvig, J. (1987) *Diabetes/Metab. Rev.* 3, 779–802.
- [7] Turk, J., Wolf, B.A. and McDaniel, M.L. (1987) *Prog. Lipid Res.* 26, 125–181.
- [8] Prentki, M. and Matschinsky, F.M. (1987) *Physiol. Rev.* 67, 1185–1248.
- [9] Wolf, B.A., Colca, J.R., Turk, J., Florholmen, J. and McDaniel, M.L. (1988) *Am. J. Physiol.* 254, E121–E136.
- [10] Wolf, B.A., Florholmen, J., Turk, J. and McDaniel, M.L. (1988) *J. Biol. Chem.* 263, 3565–3575.
- [11] Naber, S.P., McDaniel, M.L. and Lacy, P.E. (1977) *Endocrinology* 101, 686–693.
- [12] Wolf, B.A., Turk, J., Sherman, W.R. and McDaniel, M.L. (1986) *J. Biol. Chem.* 261, 3501–3511.
- [13] Gylfe, E., Buitrago, A., Berggren, P.O., Hammarstrom, K. and Hellman, B. (1978) *Am. J. Physiol.* 235, E191–E196.
- [14] Turk, J., Wolf, B.A. and McDaniel, M.L. (1986) *Biochem. J.* 237, 259–263.
- [15] Misler, S., Falke, L.C., Gillis, K. and McDaniel, M.L. (1986) *Proc. Natl. Acad. Sci. USA* 83, 7119–7123.